Pseudoexfoliation Glaucoma: Clinical Trials

1 trial for Pseudoexfoliation Glaucoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 enrolling by invitation. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Enrolling by invitation 1
Phase 21Enrolling by invitation 1

Follow Pseudoexfoliation Glaucoma: new trials by email Literature Review of Pseudoexfoliation Glaucoma trials Research Report on Pseudoexfoliation Glaucoma

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Topical Insulin for Glaucoma (TING2)
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma
Phase 1 / Phase 2Enrolling by invitationStanford University902026-09-102026-10-13

Narrower conditions

Exfoliation Syndrome (1)  ·  Glaucoma (1)  ·  Glaucoma, Open-Angle (1)  ·  Low Tension Glaucoma (1)

Broader conditions

Eye Diseases (1)  ·  Iris Diseases (1)  ·  Ocular Hypertension (1)  ·  Optic Nerve Diseases (1)  ·  Uveal Diseases (1)

Interventions

Insulin (1)

Sponsors

Stanford University (1)

Countries

United States (1)

Top investigators

Jeffrey L Goldberg, MD PhD (1)